At Quest, we continue to prioritize molecular testing and TAT for Priority patients. Priority testing parameters are defined as hospitalized, long-term care (LTC), and presurgical patients.
Apolymerase chain reaction (PCR) molecular test using mucleic acid amplification, or NAAT (test code 39448), is available to test asymptomatic and symptomatic patients for COVID-19. Through qualitative multi-target molecular diagnosis, this testing option helps to detect the presence of SARS-CoV-2.
Quest processes 4 different molecular test: an FDA emergency use-authorized Quest Diagnostics lab-developed test (LDT); an FDA emergency use-authorized Roche Diagnostics® test; an FDA emergency use-authorize Hologic® Panther Fusion® test; and an FDA emergency use-authorized Hologic Panther COVID-19 molecular assay.